Khiron is taking a different approach than US Cannabis companies.
They are building data systems to provide evidence-based research to reduce stigma, adopt normalization, and convert opioid users to medical cannabis. Their systems and achievement have quickly led to many breakthroughs, as recently announced, “Khiron signs deal with Bogota’s largest public health insurance for medical cannabis coverage.” Now that Columbia is on board, Khiron has its eyes on disrupting other international medical markets by taking the data-based evidence to Brazil, Peru, Mexico, and many others
This week on The Dime, we host Alvaro Torres, CEO of Khiron, to discuss
- Providing data-based evidence to influence regulators
- International challenges & opportunities
- Building foundational systems for personalized medicine
- How US Cannabis companies are looking to replicate Khiron’s international success
- and so much more
About Khiron
A GLOBAL MEDICAL CANNABIS COMPANY IMPROVING THE QUALITY OF PEOPLES’ LIVES.We believe in the benefits of medical cannabis to improve people’s quality of life through the development of high-quality pharmaceutical products, continuous medical education for health professionals, and permanent monitoring of the patient in their treatment, through the Patient Follow-up Program.#CannabisInsier #KHRN #GlobalCannabis
TSXV: KHRN | OTCQX: KHRNF
#cannnabisinsider #internationalcannabis #KHRNF
Khiron Links:
https://khiron.ca/
https://twitter.com/khironlife
https://www.instagram.com/khironlife/?hl=en
https://www.linkedin.com/in/alvaroftorres/?originalSubdomain=co
https://twitter.com/alvarotorresrue
Follow us: Our Links.
At Eighth Revolution (8th Rev), we provide services from capital to cannabinoid and everything in between in the cannabinoid industry.
8th Revolution Cannabinoid Playbook is an Industry-leading report covering the entire cannabis supply chain
The Dime is a top 5% most shared global podcast
The Dime is a top 50 Cannabis Podcast
Sign up for our playbook here:
🎥 YouTube: The Dime
📸 Instagram: The Dime
🐣 Twitter: Bryan Fields, Kellan Finney
